Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Chronic Renal Failure

Free Subscription Articles published in Lancet Retrieve available abstracts of 21 articles: HTML format

Single Articles

September 2026
1. RIELLA LV, Borges TJ, Rosales IA, Avillach CT, et al
   Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study.
   Lancet. 2026;408:1029-1040.
   PubMed     Abstract available
   
   
   June 2026
2. NASSIRI N, Gill IS
   Combined bladder-kidney transplantation: first-in-human feasibility trial.
   Lancet. 2026 Jun 23:S0140-6736(26)00718-X. doi: 10.1016/S0140-6736(26)00718.
   PubMed     Abstract available
   
   
   
3. THE LANCET
   The next steps for chronic kidney disease.
   Lancet. 2026;407:2345.
   PubMed    
   
   
   
4. NEUEN BL, Heerspink HJL, Perkovic V, Cherney DZI, et al
   Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).
   Lancet. 2026;407:2375-2386.
   PubMed     Abstract available
   
   
   
5. LEES JS, Skoberne A, Zhang L, Wyatt C, et al
   Chronic kidney disease, complex conditions, and advancing therapeutics: new hope and challenges.
   Lancet. 2026 Jun 3:S0140-6736(26)00653-7. doi: 10.1016/S0140-6736(26)00653.
   PubMed     Abstract available
   
   
   
6. LEES JS, Zhang L, Anandh U, Kronbichler A, et al
   Advances in the diagnosis and detection of chronic kidney disease.
   Lancet. 2026 Jun 3:S0140-6736(26)00702-6. doi: 10.1016/S0140-6736(26)00702.
   PubMed     Abstract available
   
   
   April 2026
7. ZENG G, Bidel Z, Yang Q, Canoy D, et al
   Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.
   Lancet. 2026;407:1626-1638.
   PubMed     Abstract available
   
   
   
8. SUN Y, Guo X
   Cardiovascular benefit of blood-pressure lowering in chronic kidney disease.
   Lancet. 2026;407:1578-1580.
   PubMed    
   
   
   November 2025
9. HERRINGTON WG, Judge PK, Grams ME, Wanner C, et al
   Chronic kidney disease.
   Lancet. 2025 Nov 25:S0140-6736(25)01942-7. doi: 10.1016/S0140-6736(25)01942.
   PubMed     Abstract available
   
   
   
10. THE LANCET
    Chronic kidney disease: breaking the silence.
    Lancet. 2025;406:2393.
    PubMed    
    
    
    
11. HEERSPINK HJL, Cardona JF, Jolly S, Pergola PE, et al
    Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.
    Lancet. 2025 Nov 8:S0140-6736(25)02014-8. doi: 10.1016/S0140-6736(25)02014.
    PubMed     Abstract available
    
    
    
12. JHA V
    Augmenting nephroprotection: balcinrenone plus dapagliflozin in chronic kidney disease.
    Lancet. 2025 Nov 8:S0140-6736(25)02126-9. doi: 10.1016/S0140-6736(25)02126.
    PubMed    
    
    
    
13. 
    Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Nov 7:S0140-6736(25)01853-7. doi: 10.1016/S0140-6736(25)01853.
    PubMed     Abstract available
    
    
    August 2025
14. PYNE L, Rossignol P, Giles C, Junek M, et al
    Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials.
    Lancet. 2025;406:811-820.
    PubMed     Abstract available
    
    
    
15. SOOMRO QH, Charytan DM
    Requiem for mineralocorticoid blockade in maintenance dialysis.
    Lancet. 2025;406:780-782.
    PubMed    
    
    
    
16. ROSSIGNOL P, Zannad F, Massy Z, Azizi M, et al
    Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.
    Lancet. 2025;406:705-718.
    PubMed     Abstract available
    
    
    
17. WALSH M, Collister D, Gallagher M, Mark PB, et al
    Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial.
    Lancet. 2025;406:695-704.
    PubMed     Abstract available
    
    
    May 2025
18. LOU-MEDA R, Perez JB
    Reducing the burden of chronic kidney disease in the world.
    Lancet. 2025 May 9:S0140-6736(25)00548-3. doi: 10.1016/S0140-6736(25)00548.
    PubMed    
    
    
    October 2024
19. RANCHIN B, Shroff R
    Haemodiafiltration improves survival in patients receiving dialysis.
    Lancet. 2024 Oct 25:S0140-6736(24)01938-X. doi: 10.1016/S0140-6736(24)01938.
    PubMed    
    
    
    August 2024
20. MARECEK R, Kissling S, Teso AD, Vuignier Y, et al
    Chronic metabolic acidosis in a patient with diabetes on maintenance haemodialysis: mind the anion gap.
    Lancet. 2024;404:570-571.
    PubMed    
    
    
    March 2024
21. WONG K, Pitcher D, Braddon F, Downward L, et al
    Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort.
    Lancet. 2024;403:1279-1289.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Renal Failure is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum